AzTrials
AzTrials

Prevention & ControlPhase 3COMPASSNCT01776424

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

A Phase 3 study testing Rivaroxaban (Xarelto, BAY59-7939), Aspirin and Pantoprazole in people with Prevention & Control, run by Bayer at 565 sites in 33 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The primary objectives of this study are: To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with coronary artery disease (CAD) or peripheral… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Prevention & Control
What is being tested?
Rivaroxaban (Xarelto, BAY59-7939), Aspirin and Pantoprazole
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
27,395 participants
Where
565 sitesin 33 countries
Study dates
28 Feb 2013to 15 Jun 2021
Phase
Phase 3

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Meet criteria for CAD and/or PAD
  • Subjects with CAD must also meet at least one of the following criteria:
  • Age ≥65, or
  • Age <65 and documented atherosclerosis or revascularization involving at least 2 vascular beds, or at least 2 additional risk factors

Who cannot join

  • Stroke within 1 month or any history of hemorrhagic or lacunar stroke
  • Severe heart failure with known ejection fraction <30% or New York Heart Association (NYHA) class III or IV symptoms
  • Estimated glomerular filtration rate (eGFR)<15 mL/min
  • Need for dual antiplatelet therapy, other non-aspirin antiplatelet therapy, or oral anticoagulant therapy

Trial locations and contacts

565 sites in 33 countries.

565 sites in 33 countries

United States53 sites

  • Study site

    Alpena, Michigan, 49707

  • Study site

    Anaheim, California, 92801

  • Study site

    Arlington Heights, Illinois, 60005

  • Study site

    Atlantis, Florida, 33462

  • Study site

    Baltimore, Maryland, 21215

  • Study site

    Bellevue, Washington, 98004-4623

  • Study site

    Birmingham, Alabama, 35294

  • Study site

    Clearwater, Florida, 33756

  • Study site

    Coral Springs, Florida, 33065

  • Study site

    Cortlandt Manor, New York, 10567

  • Study site

    Crestview Hills, Kentucky, 41017-5460

  • Study site

    Dallas, Texas, 75216-7167

  • Study site

    Davenport, Iowa, 52803

  • Study site

    Doylestown, Pennsylvania, 18901

  • Study site

    Durham, North Carolina, 27713

  • Study site

    Elyria, Ohio, 44035

  • Study site

    Haverhill, Massachusetts, 01830

  • Study site

    Hazel Crest, Illinois, 60429

  • Study site

    Houston, Texas, 77030-4298

  • Study site

    Houston, Texas, 77030

  • Study site

    Jackson, Michigan, 49201

  • Study site

    Jacksonville Beach, Florida, 32250

  • Study site

    Kalispell, Montana, 59901

  • Study site

    Kingston, New York, 12401

  • Study site

    Laguna Hills, California, 92653

  • Study site

    Langhorne, Pennsylvania, 19047

  • Study site

    Largo, Florida, 33770

  • Study site

    Meridian, Idaho, 83716

  • Study site

    Mobile, Alabama, 36608

  • Study site

    New Brunswick, New Jersey, 08901

  • Study site

    New Port Richey, Florida, 34653

  • Study site

    Northridge, California, 91324

  • Study site

    Norwalk, Connecticut, 06851

  • Study site

    Palo Alto, California, 94304-1207

  • Study site

    Pinehurst, North Carolina, 28374

  • Study site

    Puyallup, Washington, 98372

  • Study site

    Safety Harbor, Florida, 34695

  • Study site

    San Antonio, Texas, 78229

  • Study site

    Sandusky, Ohio, 44870

  • Study site

    Santa Rosa, California, 95494

  • Study site

    Sarasota, Florida, 34239

  • Study site

    Saratoga Springs, New York, 12866

  • Study site

    Seattle, Washington, 98195

  • Study site

    Sioux Falls, South Dakota, 57108

  • Study site

    Spokane, Washington, 99204

  • Study site

    St Louis, Missouri, 63136

  • Study site

    Stamford, Connecticut, 06905

  • Study site

    Sylmar, California, 91342

  • Study site

    Toledo, Ohio, 43606

  • Study site

    Torrance, California, 90502-2004

  • Study site

    Trumbull, Connecticut, 06611

  • Study site

    West Des Moines, Iowa, 50266

  • Study site

    Yardley, Pennsylvania, 19067

Other trials in United States

Japan48 sites

  • Study site

    Akishima, Tokyo, 196-0003

  • Study site

    Asahikawa, Hokkaido, 070-0038

  • Study site

    Asahikawa, Hokkaido, 070-8610

  • Study site

    Bunkyo-ku, Tokyo, 113-8431

  • Study site

    Chiba, 263-0043

  • Study site

    Fukuoka, 812-0033

  • Study site

    Fukuoka, 814-0180

  • Study site

    Gifu, 500-8384

  • Study site

    Gifu, 500-8717

  • Study site

    Imabari, Ehime, 794-0006

  • Study site

    Itabashi-ku, Tokyo, 173-8610

  • Study site

    Kaga, Ishikawa-ken, 922-8522

  • Study site

    Kasuga, Fukuoka, 816-0864

  • Study site

    Kisarazu, Chiba, 292-8535

  • Study site

    Kishiwada, Osaka, 596-0042

  • Study site

    Kitakyushu, Fukuoka, 802-8555

  • Study site

    Kobe, Hyōgo, 654-0026

  • Study site

    Komatsushimachō, Tokushima, 773-8502

  • Study site

    Kumamoto, 861-4193

  • Study site

    Kyoto, 600-8558

  • Study site

    Kyoto, 601-1495

  • Study site

    Kyoto, 615-8256

  • Study site

    Maebashi, Gunma, 371-0821

  • Study site

    Matsudo, Chiba, 270-2251

  • Study site

    Matsuyama, Ehime, 790-0062

  • Study site

    Miura-gun, Kanagawa, 240-0116

  • Study site

    Miyako-gun, Fukuoka, 800-0344

  • Study site

    Nagoya, Aichi-ken, 453-8511

  • Study site

    Naha, Okinawa, 902-8511

  • Study site

    Onga-gun, Fukuoka, 811-4342

  • Study site

    Onomichi, Hiroshima, 722-8503

  • Study site

    Osaka, 530-0001

  • Study site

    Osaka, 530-8480

  • Study site

    Osaka, 540-0006

  • Study site

    Osaka, 543-0035

  • Study site

    Osaka, 558-8558

  • Study site

    Osaka, 559-0012

  • Study site

    Sagamihara, Kanagawa, 252-0375

  • Study site

    Sapporo, Hokkaido, 006-0852

  • Study site

    Sapporo, Hokkaido, 006-8555

  • Study site

    Sapporo, Hokkaido, 060-0004

  • Study site

    Shimonoseki, Yamaguchi, 750-0061

  • Study site

    Takarazuka, Hyōgo, 665-0873

  • Study site

    Takatsuki, Osaka, 569-1096

  • Study site

    Tokorozawa, Saitama, 359-1141

  • Study site

    Tomakomai, Hokkaido, 053-8567

  • Study site

    Toyoake, Aichi-ken, 470-1192

  • Study site

    Yokohama, Kanagawa, 232-0024

Other trials in Japan

Canada46 sites

  • Study site

    Brampton, Ontario, L6W 2X7

  • Study site

    Burlington, Ontario, L7M 4Y1

  • Study site

    Burlington, Ontario, L7R 1E2

  • Study site

    Calgary, Alberta, T2N 4Z6

  • Study site

    Cambridge, Ontario, N1R 6V6

  • Study site

    Cambridge, Ontario, N1R 7R1

  • Study site

    Chicoutimi, Quebec, G7H 5H6

  • Study site

    Edmonton, Alberta, T6G 2B7

  • Study site

    Greater Sudbury, Ontario, P3E 1H5

  • Study site

    Greater Sudbury, Ontario, P3E 6C3

  • Study site

    Grimsby, Ontario, L3M 1P3

  • Study site

    Halifax, Nova Scotia, B3H 3A7

  • Study site

    Hamilton, Ontario, L8L 2X2

  • Study site

    Hamilton, Ontario, L8M 1K7

  • Study site

    Laval, Quebec, H7M 3L9

  • Study site

    Lévis, Quebec, G6V 4Z5

  • Study site

    London, Ontario, N6A 5A5

  • Study site

    London, Ontario, N6G 2M1

  • Study site

    Mississauga, Ontario, L5K 2L3

  • Study site

    Moncton, New Brunswick, E1G 1A7

  • Study site

    Montreal, Quebec, H2W 1T8

  • Study site

    Montreal, Quebec, H3G 1A4

  • Study site

    New Westminster, British Columbia, V3L 3W4

  • Study site

    Newmarket, Ontario, L3Y 2P6

  • Study site

    Newmarket, Ontario, L3Y 8C3

  • Study site

    Oakville, Ontario, L6K 3W7

  • Study site

    Ontario, P3E 5M4

  • Study site

    Oshawa, Ontario, L1J 2J9

  • Study site

    Oshawa, Ontario, L1J 2K1

  • Study site

    Ottawa, Ontario, K2H 8T5

  • Study site

    Peterborough, Ontario, K9J 0B2

  • Study site

    Québec, G1V 4G5

  • Study site

    Saint John, New Brunswick, E2L 4L2

  • Study site

    Scarborough Village, Ontario, M1E 5E9

  • Study site

    Sherbrooke, Quebec, J1H 5N4

  • Study site

    Terrebonne, Quebec, J6V 2H2

  • Study site

    Thetford-Mines, Quebec, G6G 2V4

  • Study site

    Toronto, Ontario, M4N 3M5

  • Study site

    Trois-Rivières, Quebec, G8Z 4K4

  • Study site

    Victoria, British Columbia, V8R 4R2

  • Study site

    Waterloo, Ontario, ON N2T 0C1

  • Study site

    Windsor, Ontario, N8X 5A6

  • Study site

    Winnipeg, Manitoba, R2H 0R8

  • Study site

    Winnipeg, Manitoba, R2H 2A6

  • Study site

    Winnipeg, Manitoba, R2V 4W3

  • Study site

    Winnipeg, Manitoba, R3T 2E8

Other trials in Canada

Argentina45 sites

  • Study site

    Adrogué, Buenos Aires, 1846

  • Study site

    Bahía Blanca, Buenos Aires, 8000

  • Study site

    Buenos Aires, Ciudad Auton. de Buenos Aires, C1119ACN

  • Study site

    Buenos Aires, Ciudad Auton. de Buenos Aires, C1428ART

  • Study site

    Buenos Aires, Ciudad Auton. de Buenos Aires, C1440AAD

  • Study site

    Ciudad Auton. de Buenos Aires, C1023AAB

  • Study site

    Ciudad Auton. de Buenos Aires, C1181ACL

  • Study site

    Ciudad Auton. de Buenos Aires, C1405BUB

  • Study site

    Ciudad Autón. de Buenos Aires, Ciudad Auton. de Buenos Aires, C1425AGC

  • Study site

    Córdoba, X5000AAW Córdoba

  • Study site

    Córdoba, X5000AAX

  • Study site

    Córdoba, X5003DCE

  • Study site

    Córdoba, X5003DCP

  • Study site

    Córdoba, X5004CDT

  • Study site

    Córdoba, X5006IKK

  • Study site

    Coronel Suárez, Buenos Aires, B7540GHD

  • Study site

    Corrientes, 3400

  • Study site

    Junín, Buenos Aires, B6000BHA

  • Study site

    La Plata, Buenos Aires, 1900

  • Study site

    La Plata, Buenos Aires, B1902AGY

  • Study site

    La Plata, Buenos Aires, B1902CNF

  • Study site

    La Plata, Buenos Aires, B1902COS

  • Study site

    Mar del Plata, Buenos Aires, B7600FZN

  • Study site

    Merlo, Buenos Aires, B1722COV

  • Study site

    Munro, Buenos Aires, B1605DSX

  • Study site

    Quilmes, Buenos Aires, 1878

  • Study site

    Rafaela, Santa Fe Province, S2300MMA

  • Study site

    Ramos Mejía, Buenos Aires, B1740ETD

  • Study site

    Rosario, Santa Fe Province, 2000

  • Study site

    Rosario, Santa Fe Province, S2005PAF

  • Study site

    Rosario, Santa Fe Province

  • Study site

    Salta, A4406CLA

  • Study site

    San Juan, 5400

  • Study site

    San Luis, 5700

  • Study site

    San Martín, Buenos Aires, 1650

  • Study site

    San Miguel de Tucumán, Tucumán Province, 4000

  • Study site

    San Miguel de Tucumán, Tucumán Province, T4000IFL

  • Study site

    San Nicolás de los Arroyos, Buenos Aires, B2900DMH

  • Study site

    Santa Fe, S3000FWO

  • Study site

    Santa Rosa, La Pampa Province, 6300

  • Study site

    Venado Tuerto, Santa Fe Province, S2600KUE

  • Study site

    Vicente López, Buenos Aires, B1602ABQ

  • Study site

    Villa Allende, Córdoba Province

  • Study site

    Villa María, Córdoba Province, X5900JKA

  • Study site

    Zárate, Buenos Aires, B2800DGH

Other trials in Argentina

China27 sites

  • Study site

    Beijing, 100029

  • Study site

    Beijing, 100034

  • Study site

    Beijing, 100038

  • Study site

    Beijing, 100088

  • Study site

    Beijing, 100730

  • Study site

    Beijing

  • Study site

    Changchun, Jilin, 130000

  • Study site

    Changchun, Jilin, 130033

  • Study site

    Changsha, Hunan, 410011

  • Study site

    Chengdu, Sichuan, 610041

  • Study site

    Guangzhou, Guangdong, 510080

  • Study site

    Guangzhou, Guangdong, 510100

  • Study site

    Hangzhou, Zhejiang, 310003

  • Study site

    Hangzhou, Zhejiang, 310016

  • Study site

    Nanjing, Jiangsu, 210006

  • Study site

    Nanjing, Jiangsu, 210029

  • Study site

    Shanghai, 200001

  • Study site

    Shanghai, 200003

  • Study site

    Shanghai, 200025

  • Study site

    Shanghai, 200030

  • Study site

    Shanghai, 200032

  • Study site

    Shanghai, 200080

  • Study site

    Shenyang, Liaoning, 110004

  • Study site

    Wenzhou, Zhejiang, 325000

  • Study site

    Wudan, Hubei, 430022

  • Study site

    Wuhan, Hubei

  • Study site

    Xi’an, Shanxi, 710061

Other trials in China

Netherlands27 sites

  • Study site

    's-Hertogenbosch, 5223 GZ

  • Study site

    Amsterdam, 1091 AC

  • Study site

    Apeldoorn, 7334 DZ

  • Study site

    Arnhem, 6815 AD

  • Study site

    Breda, 4818 CK

  • Study site

    Delft, 2625 AD

  • Study site

    Deventer, 7416 SE

  • Study site

    Doetinchem, 7009 BL

  • Study site

    Drachten, 9205 NN

  • Study site

    Ede, 6716 RP

  • Study site

    Gorinchem, 4204 AA

  • Study site

    Gouda, 2803 HH

  • Study site

    Groningen, 9721 SW

  • Study site

    Heerlen, 6401 CX

  • Study site

    Helmond, 5707 HA

  • Study site

    Hoogeveen, 7909 AA

  • Study site

    Hoorn, 1624 NP

  • Study site

    Leeuwarden, 8901 BR

  • Study site

    Meppel, 7943 KA

  • Study site

    Nijmegen, 6532 SZ

  • Study site

    Roermond, 6043 CV

  • Study site

    Roosendaal, 4708 AE

  • Study site

    Rotterdam, 3045 PM

  • Study site

    Rotterdam, 3083 AN

  • Study site

    Sneek, 8601 ZK

  • Study site

    Tiel, 4002 WP

  • Study site

    Zwolle, 8011 JW

Other trials in Netherlands

Czechia26 sites

  • Study site

    Brno, 625 00

  • Study site

    Brno, 656 91

  • Study site

    České Budějovice, 370 01

  • Study site

    Český Krumlov, 381 27

  • Study site

    Hodonín, 695 01

  • Study site

    Hradec Králové, 500 05

  • Study site

    Jablonec nad Nisou, 466 60

  • Study site

    Kolín, 280 02

  • Study site

    Liberec, 460 63

  • Study site

    Olomouc, 779 00

  • Study site

    Ostrava, 708 52

  • Study site

    Ostrava, 728 80

  • Study site

    Pardubice, 530 03

  • Study site

    Prague, 100 34

  • Study site

    Prague, 128 08

  • Study site

    Prague, 140 21

  • Study site

    Prague, 150 06

  • Study site

    Prague, 150 30

  • Study site

    Prague, 158 00

  • Study site

    Prague, 169 02

  • Study site

    Slaný, 274 01

  • Study site

    Sušice, 342 01

  • Study site

    Třebíč, 674 01

  • Study site

    Třinec, 739 61

  • Study site

    Uherské Hradiště, 686 68

  • Study site

    Zlín, 762 75

Other trials in Czechia

Brazil23 sites

  • Study site

    Belo Horizonte, Minas Gerais, 30150-240

  • Study site

    Blumenau, Santa Catarina, 89010 500

  • Study site

    Campina Grande do Sul, Paraná, 83430 000

  • Study site

    Campinas, São Paulo, 13010-001

  • Study site

    Campinas, São Paulo, 13020-421

  • Study site

    Campinas, São Paulo, 13060904

  • Study site

    Canoas, Rio Grande do Sul, 92425-900

  • Study site

    Curitiba, Paraná, 80730-150

  • Study site

    Goiânia, Goiás, 74223 130

  • Study site

    Matão, São Paulo, 15990-060

  • Study site

    Pelotas, Rio Grande do Sul, 96015-290

  • Study site

    Porto Alegre, Rio Grande do Sul, 90.620-001

  • Study site

    Porto Alegre, Rio Grande do Sul, 90020-090

  • Study site

    Porto Alegre, Rio Grande do Sul, 90840-440

  • Study site

    Porto Alegre, Rio Grande do Sul

  • Study site

    São José do Rio Preto, São Paulo, 15015-750

  • Study site

    São José do Rio Preto, São Paulo, 15090

  • Study site

    São Paulo, São Paulo, 01506-001

  • Study site

    São Paulo, São Paulo, 04012-909

  • Study site

    São Paulo, 05403-000

  • Study site

    Uberaba, Minas Gerais, 38025-260

  • Study site

    Uberlândia, Minas Gerais, 38400-368

  • Study site

    Votuporanga, São Paulo

Other trials in Brazil

Italy21 sites

  • Study site

    Ancona, The Marches, 60126

  • Study site

    Arezzo, Tuscany, 52044

  • Study site

    Bologna, Emilia-Romagna, 40133

  • Study site

    Brescia, Lombardy, 25123

  • Study site

    Caserta, Campania, 81027

  • Study site

    Catania, Sicily, 95126

  • Study site

    Cremona, Lombardy, 26100

  • Study site

    Florence, Tuscany, 50053

  • Study site

    Foggia, Apulia, 71100

  • Study site

    Forlì Cesena, Emilia-Romagna, 47100

  • Study site

    Isernia, Molise, 86170

  • Study site

    Lecce, Apulia, 73042

  • Study site

    Palermo, Sicily, 90146

  • Study site

    Pavia, Lombardy, 27100

  • Study site

    Perugia, Umbria, 06024

  • Study site

    Ravenna, Emilia-Romagna, 48010

  • Study site

    Terni, Umbria, 05100

  • Study site

    Trieste, Friuli Venezia Giulia, 34149

  • Study site

    Udine, Friuli Venezia Giulia, 33038

  • Study site

    Udine, Friuli Venezia Giulia, 33057

  • Study site

    Udine, Friuli Venezia Giulia

Other trials in Italy

Australia18 sites

  • Study site

    Adelaide, South Australia, 5042

  • Study site

    Birtinya, Queensland, 4575

  • Study site

    Brisbane, Queensland, 4029

  • Study site

    Brisbane, Queensland, 4064

  • Study site

    Bruce, Australian Capital Territory, 2617

  • Study site

    Geelong, Victoria, 3220

  • Study site

    Gosford, New South Wales, 2250

  • Study site

    Hobart, Tasmania, 7000

  • Study site

    Launceston, Tasmania, 7250

  • Study site

    Melbourne, Victoria, 3052

  • Study site

    Melbourne, Victoria, 3181

  • Study site

    Murdoch, Western Australia, 6150

  • Study site

    Nedlands, Western Australia, 6009

  • Study site

    New Lambton Heights, New South Wales, 2305

  • Study site

    Prahran, Victoria, 3181

  • Study site

    Redcliffe, Queensland, 4020

  • Study site

    Taree, New South Wales, 2430

  • Study site

    Woolloongabba, Queensland, 4102

Other trials in Australia

Germany18 sites

  • Study site

    Bad Homburg, Hesse, 61348

  • Study site

    Berlin, 12351

  • Study site

    Berlin, 12559

  • Study site

    Berlin, 13353

  • Study site

    Bielefeld, North Rhine-Westphalia, 33604

  • Study site

    Bottrop, 46242

  • Study site

    Dortmund, North Rhine-Westphalia, 44137

  • Study site

    Dresden, Saxony, 01067

  • Study site

    Frankfurt, 65929

  • Study site

    Frankfurt am Main, Hesse, 60596

  • Study site

    Hamburg, 20099

  • Study site

    Kassel, Hesse, 34128

  • Study site

    Leipzig, Saxony, 04289

  • Study site

    Magdeburg, Saxony-Anhalt, 39120

  • Study site

    Nuremberg, Bavaria, 90402

  • Study site

    Warendorf, 48231

  • Study site

    Wuppertal, North Rhine-Westphalia, 42117

  • Study site

    Würzburg, Bavaria, 97078

Other trials in Germany

Philippines16 sites

  • Study site

    Batangas

  • Study site

    Cebu City, 6000

  • Study site

    City of Muntinlupa, 1780

  • Study site

    Dagupan, 2400

  • Study site

    Dasmariñas, 4114

  • Study site

    Iloilo City, 5000

  • Study site

    Laoag, 2900

  • Study site

    Manila, 1000

  • Study site

    Manila

  • Study site

    Metro Manila, 1502

  • Study site

    Palawan, 5300

  • Study site

    Pasig, 1605

  • Study site

    Quezon City, 1102

  • Study site

    Quezon City, 1109

  • Study site

    Quezon City, NCR 1100

  • Study site

    Tacloban City, 6500

Other trials in Philippines

Romania16 sites

  • Study site

    Brasov, 500326

  • Study site

    Bucharest, 011461

  • Study site

    Bucharest, 021659

  • Study site

    Bucharest, 022322

  • Study site

    Bucharest, 041915

  • Study site

    Bucharest, 042122

  • Study site

    Bucharest, 050098

  • Study site

    Bucharest, 061114

  • Study site

    Bucharest, 50659

  • Study site

    Cluj-Napoca, 400001

  • Study site

    Iași, 700503

  • Study site

    Iași, 700732

  • Study site

    Târgu Mureş, 540124

  • Study site

    Târgu Mureş, 540136

  • Study site

    Timișoara, Timiș County, 300254

  • Study site

    Timișoara, 300310

Other trials in Romania

Ukraine14 sites

  • Study site

    Dnipropetrovsk, 49 006

  • Study site

    Kharkiv, 61002

  • Study site

    Kharkiv, 61039

  • Study site

    Kharkiv, 61176

  • Study site

    Kiev, 02 091

  • Study site

    Kiev, 02660

  • Study site

    Kiev, 03 049

  • Study site

    Lviv, 790 34

  • Study site

    Lviv, 79044

  • Study site

    Lviv, 79659

  • Study site

    Simferopol, 95006

  • Study site

    Vinnitsa, 21029

  • Study site

    Zaporizhzhya, 69 000

  • Study site

    Zaporizhzhya, 69118

Other trials in Ukraine

United Kingdom14 sites

  • Study site

    Basildon, Essex, SS16 5NL

  • Study site

    Belfast, Antrim, BT16 1RH

  • Study site

    Blackpool, Lancashire, FY4 3AD

  • Study site

    Hardwick, Stockton-on-Tees, TS29 6NH

  • Study site

    Harrow, London, HA1 3UJ

  • Study site

    Londonderry Co. Londonderry, Derry, BT47 6SB

  • Study site

    Middlesbrough, North Yorkshire, TS4 3BW

  • Study site

    Northampton, Northamptonshire, NN1 5BD

  • Study site

    Nuneaton, Warwickshire, CV10 7DJ

  • Study site

    Portadown, North Ireland

  • Study site

    Stevenage, Hertfordshire, SG1 4AB

  • Study site

    West Bromich, West Midlands, B71 4HJ

  • Study site

    Wolverhampton, West Midlands, WV10 0QP

  • Study site

    Worcester, Worcestershire, WR5 1DD

Other trials in United Kingdom

Colombia13 sites

  • Study site

    Armenia, Quindío Department

  • Study site

    Barranquilla, Atlántico

  • Study site

    Barranquilla

  • Study site

    Bogotá

  • Study site

    Bucaramanga, Santander Department

  • Study site

    Cali, Valle del Cauca Department, 760032

  • Study site

    Cartagena, Departamento de Bolívar

  • Study site

    Espinal, Tolima Department

  • Study site

    Floridablanca, Santander Department, 681004

  • Study site

    Manizales, Caldas Department

  • Study site

    Montería, Departamento de Córdoba, 230002

  • Study site

    Pasto, Departamento de Nariño

  • Study site

    Pereira, Risaralda Department

Other trials in Colombia

Russia12 sites

  • Study site

    Barnaul, 656038

  • Study site

    Kemerovo, 650002

  • Study site

    Moscow, 101990

  • Study site

    Moscow, 107084

  • Study site

    Moscow, 111539

  • Study site

    Moscow, 117556

  • Study site

    Moscow, 119435

  • Study site

    Moscow, 121309

  • Study site

    Moscow, 127206

  • Study site

    Novosibirsk, 630089

  • Study site

    Tomsk, 634012

  • Study site

    Zhukovskiy, 140160

Other trials in Russia

Belgium11 sites

  • Study site

    Antwerp, 2020

  • Study site

    Bonheiden, 2820

  • Study site

    Bruges, 8000

  • Study site

    Bruxelles - Brussel, 1070

  • Study site

    Charleroi, 6000

  • Study site

    Genk, 3600

  • Study site

    Hasselt, 3500

  • Study site

    Kortrijk, 8500

  • Study site

    Leuven, 3000

  • Study site

    Liège, 4000

  • Study site

    Roeselare, 8800

Other trials in Belgium

Chile11 sites

  • Study site

    Concepción, Bío-Bío, 4070038

  • Study site

    Osorno, Los Lagos Region, 5311092

  • Study site

    Providencia, Santiago Metropolitan, 7500520

  • Study site

    San Miguel, Santiago Metropolitan, 8910108

  • Study site

    Santiago, 7500739

  • Study site

    Santiago

  • Study site

    Temuco, Araucania, 2170000

  • Study site

    Temuco, Araucania, 4781156

  • Study site

    Temuco, Araucania, 4791348

  • Study site

    Valdivia, Los Lagos Region

  • Study site

    Viña del Mar, Valparaiso, 2570017

Other trials in Chile

Hungary11 sites

  • Study site

    Balatonfüred, 8230

  • Study site

    Budapest, 1085

  • Study site

    Budapest, 1115

  • Study site

    Budapest, H-1096

  • Study site

    Budapest, H-1125

  • Study site

    Debrecen, 4032

  • Study site

    Mosonmagyaróvár, 9200

  • Study site

    Pécs, 7624

  • Study site

    Sopron, 9400

  • Study site

    Székesfehérvár, 8000

  • Study site

    Szekszárd, 7100

Other trials in Hungary

Sweden11 sites

  • Study site

    Gothenburg, 413 45

  • Study site

    Helsingborg, 251 87

  • Study site

    Kristianstad, 291 85

  • Study site

    Örebro, 701 85

  • Study site

    Östersund, 831 83

  • Study site

    Skellefteå, 931 86

  • Study site

    Stockholm, 111 35

  • Study site

    Stockholm, 114 46

  • Study site

    Stockholm, 141 86

  • Study site

    Stockholm, 171 76

  • Study site

    Vällingby, 162 68

Other trials in Sweden

France10 sites

  • Study site

    Amiens, 80054

  • Study site

    Clermont-Ferrand, 63000

  • Study site

    Limoges, 87042

  • Study site

    Montpellier, 34059

  • Study site

    Nice, 06280

  • Study site

    Nîmes, 30029

  • Study site

    Paris, 75012

  • Study site

    Paris, 75018

  • Study site

    Paris, 75908

  • Study site

    Saint-Priest-en-Jarez, 42270

Other trials in France

Israel10 sites

  • Study site

    Afula, 1834111

  • Study site

    Ashkelon, 7830604

  • Study site

    Bnei Brak

  • Study site

    Haifa, 3109601

  • Study site

    Haifa, 3436212

  • Study site

    Holon, 5822012

  • Study site

    Nahariya, 2210001

  • Study site

    Safed, 1311001

  • Study site

    Tel Aviv, 64239

  • Study site

    Tel Aviv

Other trials in Israel

South Korea10 sites

  • Study site

    Busan, 614-735

  • Study site

    Daejeon, 302-718

  • Study site

    Goyang-si, Gyeonggido, 10326

  • Study site

    Jeju City, Jeju-do, 690767

  • Study site

    Seongnam-si, Gyeonggido, 463-707

  • Study site

    Seoul, Seoul Teugbyeolsi, 150-713

  • Study site

    Seoul, 03722

  • Study site

    Seoul, 110-744

  • Study site

    Seoul, 134-727

  • Study site

    Wŏnju, Gang''weondo, 26426

Other trials in South Korea

Denmark9 sites

  • Study site

    Aalborg, DK-9000

  • Study site

    Aarhus N, 8200

  • Study site

    Copenhagen, DK-2400

  • Study site

    Hellerup, 2900

  • Study site

    Holbæk, 4300

  • Study site

    Hvidovre, 2650

  • Study site

    København Ø, 2100

  • Study site

    Kolding, 6000

  • Study site

    Viborg, 8800

Other trials in Denmark

Poland9 sites

  • Study site

    Gdansk, 80 -126

  • Study site

    Kielce, 25-315

  • Study site

    Krakow, 30-002

  • Study site

    Krakow, 31-271

  • Study site

    Krakow, 31-501

  • Study site

    Krakow, 31-534

  • Study site

    Lodz, 91-347

  • Study site

    Tarnów, 33-100

  • Study site

    Wroclaw, 53-114

Other trials in Poland

South Africa9 sites

  • Study site

    Bloemfontein, Freestate, 9300

  • Study site

    Cape Town, Western Cape, 7531

  • Study site

    Johannesburg, Gauteng, 2157

  • Study site

    Observatory, Western Cape, 7925

  • Study site

    Pinelands, Eastern Cape, 7503

  • Study site

    Pinelands, Western Cape, 7405

  • Study site

    Port Elizabeth, Eastern Cape, 6014

  • Study site

    Somerset West, 7130

  • Study site

    Worcester, Western Cape, 6850

Other trials in South Africa

Ireland6 sites

  • Study site

    Ballinasloe, Co. Galway

  • Study site

    Cork

  • Study site

    Dublin, 9

  • Study site

    Dublin, D07 R2WY

  • Study site

    Dublin, D08 NHY1

  • Study site

    Galway

Other trials in Ireland

Malaysia6 sites

  • Study site

    Batu Caves, Selangor, 68100

  • Study site

    Kedah, 05460

  • Study site

    Kuala Lumpur, 50400

  • Study site

    Kuala Lumpur, 59100

  • Study site

    Kuala Selangor, 47000

  • Study site

    Sungai Buloh Selangor, 47000

Other trials in Malaysia

Slovakia6 sites

  • Study site

    Bratislava, 811 04

  • Study site

    Bratislava, 813 69

  • Study site

    Košice, 040 22

  • Study site

    Nitra, 94901

  • Study site

    Prešov, 080 81

  • Study site

    Vráble, 952 01

Other trials in Slovakia

Finland5 sites

  • Study site

    Kuopio, 70100

  • Study site

    Kuusankoski, 45700

  • Study site

    Tampere, 33200

  • Study site

    Turku, FIN-20520

  • Study site

    Vantaa, 01600

Other trials in Finland

Ecuador3 sites

  • Study site

    Guayaquil, Guayas

  • Study site

    Quito, Pichincha, 0

  • Study site

    Quito

Other trials in Ecuador

Switzerland1 site

  • Study site

    Lugano, Canton Ticino, 6900

Other trials in Switzerland

About this study

Official title: A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).

The primary objectives of this study are:

  • To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with coronary artery disease (CAD) or peripheral artery disease (PAD);
  • To determine whether rivaroxaban 5 mg bid compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke or cardiovascular death in subjects with CAD or PAD.
Being tested
Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Aspirin placebo, Rivaroxaban placebo, Pantoprazole
Keywords
Cardiovascular events, Rivaroxaban, Xarelto, Anticoagulant, Blood thinner, Aspirin, ASA, Coronary artery disease, CAD, Peripheral artery disease, PAD, Artery disease, Coronary artery bypass graft, Stroke, Heart attack, Angina, Arterial vascular disease, Myocardial infarction, MI, Cardiovascular Death
Medical subject headings
Coronary Artery Disease, Peripheral Arterial Disease, Stroke, Myocardial Infarction, Angina Pectoris, Heart Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Rivaroxaban (Xarelto, BAY59-7939)Drug

    Tablet, 2.5 mg, twice daily, oral

  • Rivaroxaban (Xarelto, BAY59-7939)Drug

    Tablet, 5 mg, twice daily, oral

  • AspirinDrug

    Tablet, 100 mg, once daily, oral

  • Aspirin placeboDrug

    Aspirin matching placebo, once daily, oral

  • Rivaroxaban placeboDrug

    Rivaroxaban matching placebo, twice daily, oral

  • PantoprazoleDrug

    Tablet, 40 mg, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole

  • Pantoprazole placeboDrug

    Pantoprazole matching placebo, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole placebo

Study groups in NCT01776424
Study groupRoleWhat they receive
Rivaroxaban 2.5mg + Aspirin 100mgExperimentalParticipants received rivaroxaban 2.5 mg twice daily (bid) and aspirin 100 mg once daily (od). All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a proton pump inhibitor (PPI), were additionally randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.
Receives: Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Aspirin; Drug: Pantoprazole; Drug: Pantoprazole placebo
Rivaroxaban 5mg + Aspirin PlaceboExperimentalParticipants received rivaroxaban 5 mg bid and aspirin placebo od. All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a PPI, were additionally randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.
Receives: Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Aspirin placebo; Drug: Pantoprazole; Drug: Pantoprazole placebo
Rivaroxaban Placebo + Aspirin 100mgActive comparatorParticipants received rivaroxaban placebo bid and aspirin 100 mg od. All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a PPI, were randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.
Receives: Drug: Aspirin; Drug: Rivaroxaban placebo; Drug: Pantoprazole; Drug: Pantoprazole placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death

    Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis.

    Measured: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

  2. The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

    Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).

    Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis.

    Measured: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

Secondary outcomes (3)

  1. The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death

    Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis.

    Measured: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

  2. The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death

    Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis.

    Measured: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

  3. All-cause Mortality

    Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis.

    Measured: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jan 2013 (estimated)
  2. Study start28 Feb 2013
  3. Primary completion21 Jul 2017
  4. Study completion15 Jun 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
27,395 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01776424
Sponsor's protocol ID
15786
Other IDs
2012-004180-43
Acronym
COMPASS
Status last verified
Nov 2022
First submitted
24 Jan 2013
Last updated
28 Nov 2022
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

Publications

  • Eikelboom JW, Bosch J, Connolly SJ, Tyrwitt J, Fox KAA, Muehlhofer E, Neumann C, Tasto C, Bangdiwala SI, Diaz R, Alings M, Dagenais GR, Leong DP, Lonn EM, Avezum A, Piegas LS, Widimsky P, Parkhomenko AN, Bhatt DL, Branch KRH, Probstfield JL, Lopez-Jaramillo P, Ryden L, Pogosova N, Keltai K, Keltai M, Ertl G, Stoerk S, Dans AL, Lanas F, Liang Y, Zhu J, Torp-Pedersen C, Maggioni AP, Commerford PJ, Guzik TJ, Vanassche T, Verhamme P, O'Donnell M, Tonkin AM, Varigos JD, Vinereanu D, Felix C, Kim JH, Ibrahim KS, Lewis BS, Metsarinne KP, Aboyans V, Steg PG, Hori M, Kakkar A, Anand SS, Lamy A, Sharma M, Yusuf S. Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 2;8(8):786-795. doi: 10.1093/ehjcvp/pvac023.

    PubMed 35383832

  • Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, Aboyans V, Abola MT, Branch KRH, Keltai K, Bhatt DL, Verhamme P, Fox KAA, Cook-Bruns N, Lanius V, Connolly SJ, Yusuf S. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. J Am Coll Cardiol. 2018 May 22;71(20):2306-2315. doi: 10.1016/j.jacc.2018.03.008. Epub 2018 Mar 11.

    PubMed 29540326

  • Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Stork S, Zhu J, Lopez-Jaramillo P, O'Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Jan 20;391(10117):219-229. doi: 10.1016/S0140-6736(17)32409-1. Epub 2017 Nov 10.

    PubMed 29132880

  • Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, Metsarinne K, O'Donnell M, Dans AL, Ha JW, Parkhomenko AN, Avezum AA, Lonn E, Lisheng L, Torp-Pedersen C, Widimsky P, Maggioni AP, Felix C, Keltai K, Hori M, Yusoff K, Guzik TJ, Bhatt DL, Branch KRH, Cook Bruns N, Berkowitz SD, Anand SS, Varigos JD, Fox KAA, Yusuf S; COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Jan 20;391(10117):205-218. doi: 10.1016/S0140-6736(17)32458-3. Epub 2017 Nov 10.

    PubMed 29132879

  • Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Stork S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27.

    PubMed 28844192

  • Bosch J, Eikelboom JW, Connolly SJ, Bruns NC, Lanius V, Yuan F, Misselwitz F, Chen E, Diaz R, Alings M, Lonn EM, Widimsky P, Hori M, Avezum A, Piegas LS, Bhatt DL, Branch KRH, Probstfield JL, Liang Y, Liu L, Zhu J, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Fox KAA, Kakkar A, Parkhomenko AN, Ertl G, Stork S, Keltai K, Keltai M, Ryden L, Dagenais GR, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Ha JW, Tonkin AM, Varigos JD, Lewis BS, Felix C, Yusoff K, Steg PG, Aboyans V, Metsarinne KP, Anand SS, Hart RG, Lamy A, Moayyedi P, Leong DP, Sharma M, Yusuf S. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol. 2017 Aug;33(8):1027-1035. doi: 10.1016/j.cjca.2017.06.001. Epub 2017 Jun 8.

    PubMed 28754388

  • Braunwald E. An Important Step for Thrombocardiology. N Engl J Med. 2017 Oct 5;377(14):1387-1388. doi: 10.1056/NEJMe1710241. Epub 2017 Aug 27. No abstract available.

    PubMed 28844176

  • Fauchier L, Bisson A, Angoulvant D. Rivaroxaban in Stable Cardiovascular Disease. N Engl J Med. 2018 Jan 26;378(4):395. doi: 10.1056/NEJMc1714934. No abstract available.

    PubMed 29372976

  • Berger JS. Antithrombotic therapy in peripheral artery disease. Lancet. 2018 Jan 20;391(10117):183-184. doi: 10.1016/S0140-6736(17)32847-7. Epub 2017 Nov 10. No abstract available.

    PubMed 29132877

  • Darmon A, Bhatt DL, Elbez Y, Aboyans V, Anand S, Bosch J, Branch KR, Connolly SJ, Dyal L, Eikelboom JW, Fox KAA, Keltai K, Probstfield J, Yusuf S, Abtan J, Sorbets E, Eagle KA, Ducrocq G, Steg PG. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. Eur Heart J. 2018 Mar 1;39(9):750-757a. doi: 10.1093/eurheartj/ehx658.

    PubMed 29186454

  • Verheugt FWA. Return of Oral Anticoagulation in Chronic Stable Coronary Disease. Circulation. 2018 Apr 17;137(16):1655-1657. doi: 10.1161/CIRCULATIONAHA.117.032916. No abstract available.

    PubMed 29661947

  • Fox KAA, Eikelboom JW, Anand SS, Bhatt DL, Bosch J, Connolly SJ, Harrington RA, Steg PG, Yusuf S. Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? Eur Heart J. 2019 May 7;40(18):1466-1471. doi: 10.1093/eurheartj/ehy347. No abstract available.

    PubMed 29945212

  • Sharma M, Hart RG, Smith EE, Bosch J, Yuan F, Casanova A, Eikelboom JW, Connolly SJ, Wong G, Diaz R, Lopez-Jaramillo P, Ertl G, Stork S, Dagenais GR, Lonn EM, Ryden L, Tonkin AM, Varigos JD, Bhatt DL, Branch KR, Probstfield JL, Kim JH, Ha JW, O'Donnell M, Vinereanu D, Fox KA, Liang Y, Liu L, Zhu J, Pogosova N, Maggioni AP, Avezum A, Piegas LS, Keltai K, Keltai M, Cook Bruns N, Berkowitz S, Yusuf S. Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. Int J Stroke. 2019 Apr;14(3):270-281. doi: 10.1177/1747493018784478. Epub 2018 Jul 30.

    PubMed 30058959

  • Kruger PC, Eikelboom JW, Yusuf S. Rivaroxaban with or without aspirin for prevention of cardiovascular disease. Coron Artery Dis. 2018 Aug;29(5):361-365. doi: 10.1097/MCA.0000000000000605. No abstract available.

    PubMed 29346127

  • Ademi Z, Zomer E, Tonkin A, Liew D. Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective. Int J Cardiol. 2018 Nov 1;270:54-59. doi: 10.1016/j.ijcard.2018.06.091. Epub 2018 Jun 25.

    PubMed 30220379

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in